Literature DB >> 9851823

Acoustically active lipospheres containing paclitaxel: a new therapeutic ultrasound contrast agent.

E C Unger1, T P McCreery, R H Sweitzer, V E Caldwell, Y Wu.   

Abstract

RATIONALE AND
OBJECTIVES: Paclitaxel-carrying lipospheres (MRX-552) were developed and evaluated as a new ultrasound contrast agent for chemotherapeutic drug delivery.
METHODS: Paclitaxel was suspended in soybean oil and added to an aqueous suspension of phospholipids in vials. The headspace of the vials was replaced with perfluorobutane gas; the vials were sealed, and they were agitated at 4200 rpm on a shaking device. The resulting lipospheres containing paclitaxel were studied for concentration, size, acute toxicity in mice, and acoustic activity and drug release with ultrasound. Lipospheres containing sudan black dye were produced to demonstrate the acoustically active liposphere (AAL)-ultrasound release concept.
RESULTS: Acoustically active lipospheres containing paclitaxel had a mean particle count of approximately 1 x 10(9) particles per mL and a mean size of 2.9 microns. Acute toxicity studies in mice showed a 10-fold reduction in toxicity for paclitaxel in AALs compared with free paclitaxel. The AALs reflected ultrasound as a contrast agent. Increasing amounts of ultrasound energy selectively ruptured the AALs and released the paclitaxel.
CONCLUSIONS: Acoustically active lipospheres represent a new class of acoustically active drug delivery vehicles. Future studies will assess efficacy of AALs for ultrasound-mediated drug delivery.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851823     DOI: 10.1097/00004424-199812000-00007

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  61 in total

1.  Stability analysis of ultrasound thick-shell contrast agents.

Authors:  Xiaozhen Lu; Georges L Chahine; Chao-Tsung Hsiao
Journal:  J Acoust Soc Am       Date:  2012-01       Impact factor: 1.840

Review 2.  Contrast-enhanced ultrasound for molecular imaging of angiogenesis.

Authors:  J R Eisenbrey; F Forsberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08       Impact factor: 9.236

3.  Evaluation of the temporal window for drug delivery following ultrasound-mediated membrane permeability enhancement.

Authors:  Anna Yudina; Matthieu Lepetit-Coiffé; Chrit T W Moonen
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

Review 4.  Ultrasound-responsive droplets for therapy: A review.

Authors:  H Lea-Banks; M A O'Reilly; K Hynynen
Journal:  J Control Release       Date:  2018-11-29       Impact factor: 9.776

Review 5.  Ultrasonic drug delivery--a general review.

Authors:  William G Pitt; Ghaleb A Husseini; Bryant J Staples
Journal:  Expert Opin Drug Deliv       Date:  2004-11       Impact factor: 6.648

Review 6.  [Ultrasound contrast agents: substance classes, pharmacokinetics, clinical applications, safety aspects].

Authors:  C Krestan
Journal:  Radiologe       Date:  2005-06       Impact factor: 0.635

7.  Tailoring the size distribution of ultrasound contrast agents: possible method for improving sensitivity in molecular imaging.

Authors:  Esra Talu; Kanaka Hettiarachchi; Shukui Zhao; Robert L Powell; Abraham P Lee; Marjorie L Longo; Paul A Dayton
Journal:  Mol Imaging       Date:  2007 Nov-Dec       Impact factor: 4.488

8.  Novel preparation techniques for controlling microbubble uniformity: a comparison.

Authors:  Eleanor Stride; Mohan Edirisinghe
Journal:  Med Biol Eng Comput       Date:  2009-05-12       Impact factor: 2.602

Review 9.  Cardiovascular therapeutic uses of targeted ultrasound contrast agents.

Authors:  Susan T Laing; David D McPherson
Journal:  Cardiovasc Res       Date:  2009-07-06       Impact factor: 10.787

Review 10.  Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics.

Authors:  Megan M Kaneda; Shelton Caruthers; Gregory M Lanza; Samuel A Wickline
Journal:  Ann Biomed Eng       Date:  2009-01-30       Impact factor: 3.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.